Net sales amounted to MSEK 174.9 (161.2), an increase of 8.5 percent (negative organic growth of 6.1 percent). The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 (MSEK 5.8) and a negative currency effect (MSEK 9.9). Adjusted for these two factors, underlying organic growth would have amounted to 3.7 percent.
” The supply chain situation improved during the quarter enabling us to reduce delivery time, says Ulrik Berthelsen. Looking ahead, we expect to see solid growth in 2026 driven by a combination of strong order intake, operational improvements, and commercial execution.
The gross margin was 51.1 percent (58.4) and EBITDA before non-recurring items amounted to MSEK 38.1 (46.3).
” We have a market leading portfolio of products in both surgical instruments and surgical tables and with improved product availability we will have the foundation for long-term value creation”, the Stille CEO concludes.
| MSEK | OCT-DEC 2025 | OCT-DEC 2024 | JAN-DEC 2025 | JAN-DEC 2024 |
| Net sales | 174.9 | 161.2 | 567.6 | 569.9 |
| Gross profit, % | 51.1 | 58.4 | 50.7 | 51.9 |
| EBITDA before non-recurring items | 38.1 | 46.3 | 113.8 | 142.4 |
| EBITDA before non-recurring items, % | 21.8 | 28.7 | 20.0 | 25.0 |
| EBITDA | 38.1 | 21.8 | 106.7 | 98.0 |
| EBITDA, % | 21.8 | 13.5 | 18.8 | 17.2 |
| EBIT before non-recurring items | 28.5 | 39.2 | 80.3 | 114.9 |
| EBIT before non-recurring items, % | 16.3 | 24.3 | 14.2 | 20.2 |
| EBIT | 28.5 | 14.8 | 73.2 | 70.5 |
| EBIT, % | 16.3 | 9.2 | 12.9 | 12.4 |